atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference | Psychedelic Invest

NEW YORK and BERLIN, May 23, 2024 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the appointment of Scott Braunstein, M.D., and Laurent Fischer, M.D., as independent directors of atai’s supervisory board (“Board”) subject to applicable legal requirements. Scott…

Opinion | The Minefields Ahead in Long COVID Treatment Development

Jeremy Faust is editor-in-chief of , an emergency medicine physician at Brigham and Women’s Hospital in Boston, and a public health researcher. He is author

January 24, 2024

Ginkgo Bioworks bets on protein AI model and data generation to turn flailing company around

Amid layoffs and a disintegrating share price, former investor darling Ginkgo Bioworks is trying out a new tack to find customers. The biotech this week

September 19, 2024

Intermittent fasting enhances glucose processing and intestinal health in aging mice

A study conducted in mice found that intermittent fasting brought benefits beyond weight loss, suggesting the practice could help the body better process glucose and

April 7, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.